Registre Français de la maladie de Pompe. Caractérisation d’une cohorte de 126 patients adultes
P. Laforêt, K. Laloui, B. Granger, D. Hamroun, N. Taouagh, JY. Hogrel, D. Orlikowski, F. Bouhour, A. Lacour, E. Salort-Campana, I. Penisson-Besnier, S. Sacconi, F. Zagnoli, F. Chapon, B. Eymard, C. Desnuelle, J. Pouget et le French Pompe Registry Study Group
Revue neurologique. 2013. 169:595-602.
The French Pompe registry was created in 2004 with the initial aim of studying the natural history of French patients with adult Pompe disease. Since the marketing in 2006 of enzyme replacement therapy (alglucosidase alfa, Myozyme1), the French Pompe registry has also been used to prospectively gather the biological and clinical follow-up data of all adult patients currently treated in France.
This report describes the main clinical and molecular features, at the time of inclusion in the French registry, of 126 patients followed up in 21 hospital-based neuromuscular or metabolic centers. The MFM, which has been used to evaluate the level of impairment of muscle function, appears to be a useful tool, particularly with regard to the D1 domain. Good correlations between MFM scores and 6MWT confirmed the importance of the MFM measurement in the follow-up of patients with Pompe disease.
Keywords: Pompe disease, Pompe registry, Acid alpha-glucosidase deficiency
Articles in scientific journals
The Use of Functional Scales for Clinical Evaluation of Duchenne Muscular Dystrophy
Barra TMF, Baraldi KF Revista Neurociências. 2013. 21(3):420-426. Literature review of scientific articles, books and dissertations published from 2000 to 2011, in Portuguese, English and Spanish languages to demonstrate the applicability of using Vignos scales, Egen...
Assisted bicycle training delays functional deterioration in boys with duchenne muscular dystrophy: the randomized controlled trial “no use is disuse”.
Jansen M, van Alfen N, Geurts AC, de Groot IJ. Neurorehabil Neural Repair. 2013. 27(9):816-27. Thirty boys (18 ambulant and 12 wheelchair-dependent) with a DMD were physically trained using an assisted bicycle. After 24 weeks, the total MFM score remained stable in...
Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients.
Servais L, Deconinck N, Moraux A, Benali M, Canal A, Van Parys F, Vereecke W, Wittevrongel S, Mayer M, Desguerre I, Maincent K, Themar-Noel C, Quijano-Roy S, Serari N, Voit T, Hogrel JY. Neuromuscul Disord. 2013. 23(2) : 139-48. Development of new tools to precisely...
Motor Function Measure: validation of a short form (MFM-20) for young children with neuromuscular diseases
Capucine de Lattre, Christine Payan, Carole Vuillerot, Pascal Rippert, Denis de Castro, Carole Bérard, Isabelle Poirot and the MFM-20 Study Group. Arch Phys Med Rehabil. 2013. 94 : 2218-26. Validation of MFM version useful in neuromuscular children under 7 years old,...
Responsiveness of the Motor Function Measure in Patients With Spinal Muscular Atrophy.
Vuillerot C, Payan C, Iwaz J, Ecochard R, Bérard C and the MFM Spinal Muscular Atrophy Study Group. Arch Phys Med Rehabil. 2013. 94(8) : 1555-61. Assessment in 112 patients with Spinal Muscular Atrophy (SMA) aged 5.7 to 59 years of the ability of the MFM to detect...
Quantitative MRI and loss of free ambulation in Duchenne muscular dystrophy.
Fischmann A, Hafner P, Gloor M, Schmid M, Klein A, Pohlman U, Waltz T, Gonzalez R, Haas T, Bieri O, Fischer D. J Neurol. 2013. 260(4):969-74. The purpose of this trial was to correlate quantitative MRI with functional abilities, evaluate using MFM in 22 ambulant or...